NCT00214604View on ClinicalTrials.gov

Type III Dysbetalipoproteinemia

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Hyperlipoproteinemia Type III
Interventions
DRUG

Rosuvastatin

10mg

DRUG

rosuvastatin

20mg

DRUG

pravastatin

40mg

Trial Locations (2)

Unknown

Research Site, Oslo

Research Site, Cape Town

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY